GlassScriptPhysician profile
Isabel A Cruz
NPI 1275735680
$4,317.66
in general payments reported to CMS, 2019-2025
16 companies · $765 in 2025
The $765 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $120 · 2021: $570 · 2022: $667 · 2023: $1,060 · 2024: $893 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Entertainment: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.72 |
| Entertainment | $374.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $936.94 | 2021-2025 | Precision 1, Precision7, Total30 |
| Optos, INC. | $780.89 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $534.44 | 2020-2025 | Cequa |
| Coopervision INC. | $497.02 | 2019-2024 | Myday Contact Lens, Clariti Contact Lens |
| Abb Con-Cise Optical Group LLC | $337.11 | 2021-2024 | Spectacle Lenses, Contact Lens |
| Sight Sciences, INC. | $278.73 | 2023-2024 | Tearcare System |
| Bausch & Lomb Americas INC. | $145.55 | 2023-2025 | Infuse |
| Johnson & Johnson Vision Care, INC. | $143.92 | 2023 | Acuvue |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.87 | 2019 | |
| Optovue, INC. | $101.41 | 2019 | |
| Maculogix, INC. | $91.88 | 2021 | |
| Lkc Technologies, INC. | $76.28 | 2025 | |
| Oyster Point Pharma, INC. | $20.27 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $15.49 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.